Sanofi

Vaxil BioTherapeutics appoints Dr. Terry Plasse chief medical officer

Tuesday, July 25, 2017

Vaxil Bio, an Israeli-Canadian biotech developing innovative immunotherapy treatments for cancer, announced the appointment of Dr. Terry Plasse as its chief medical officer, responsible for the company’s clinical program surrounding its drug candidate, ImMucin. Dr. Plasse brings 30 years of clinical development experience, including advancing products from IND through to commercially marketed treatments for several big-pharma companies.

[Read More]

Adimab announces platform transfer with Lilly

Friday, July 21, 2017

Adimab, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, has entered into an agreement with Eli Lilly to transfer the Adimab Platform to Lilly for the discovery and optimization of antibody-based drugs in all therapeutic areas. This technology transfer expands an ongoing collaboration between the two companies that was initiated in 2010, which has yielded several undisclosed therapeutic candidates for Lilly.

[Read More]

Ipsen appoints Dr. Alexandre Lebeaut as EVP, R&D, and chief scientific officer

Tuesday, April 18, 2017

Ipsen announced the appointment of Dr. Alexandre Lebeaut as executive vice president, R&D, and chief scientific officer, effective immediately. Dr. Lebeaut will report directly to David Meek, CEO of Ipsen, and serve on the executive leadership team. Dr. Lebeaut joined Ipsen in 2013 as senior vice president, chief development officer, Global Drug Development and was appointed interim head of R&D in December 2016.

[Read More]